Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

PURPOSE: We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration. It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanc...

Full description

Saved in:
Bibliographic Details
Main Authors: Kummar, Shivaani, Kinders, Robert, Gutierrez, Martin E., Rubinstein, Larry, Parchment, Ralph E., Phillips, Lawrence R., Ji, Jiuping, Monks, Anne, Low, Jennifer A., Chen, Alice, Murgo, Anthony J., Collins, Jerry, Steinberg, Seth M., Eliopoulos, Helen, Giranda, Vincent L., Gordon, Gary, Helman, Lee, Wiltrout, Robert, Tomaszewski, Joseph E., Doroshow, James H.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2009
Subjects:
Original Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2739635/
https://ncbi.nlm.nih.gov/pubmed/19364967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.7681
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items